TY - JOUR AU - 류종석 DA - 2017/05 PY - 2017 UR - https://www.tandfonline.com/doi/abs/10.1080/02652048.2017.1337247 UR - https://repository.hanyang.ac.kr/handle/20.500.11754/72053 AB - The aim of this study was to develop docetaxel-incorporated lipid nanoparticles (DTX-NPs) to improve the pharmacokinetic behaviour of docetaxel (DTX) after oral and parenteral administration via sustained release. DTX-NPs were prepared by nanotemplate engineering technique with palmityl alcohol as a solid lipid and Tween-40/Span-40/Myrj S40 as a surfactants mixture. Spherical DTX-NPs below 100 nm were successfully prepared with a narrow particle size distribution, 96% of incorporation efficiency and 686 times increase in DTX solubility. DTX-NPs showed a sustained release over 24 h in phosphate-buffered saline and simulated gastric and intestinal fluids, while DTX-micelles released DTX completely within 12 h. The half-maximal inhibitory concentration (IC50) of DTX-NPs against human breast cancer MCF-7 cells was 1.9 times lower than that of DTX-micelles and DTX solution. DTX-NPs demonstrated 3.7- and 2.8-fold increase in the area under the plasma concentration-time curve compared with DTX-micelles after oral and parenteral administration, respectively. PB - TAYLOR & FRANCIS LTD KW - Lipid nanoparticles KW - docetaxel KW - sustained release KW - pharmacokinetics KW - bioavailability KW - CONTROLLED DRUG-DELIVERY KW - IN-VIVO EVALUATION KW - ANTICANCER DRUGS KW - TUMOR MICROENVIRONMENT KW - VITRO KW - CYTOTOXICITY KW - NANOCARRIERS KW - CARRIERS KW - SYSTEMS KW - SLN TI - Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration IS - 3 VL - 34 DO - 10.1080/02652048.2017.1337247 T2 - JOURNAL OF MICROENCAPSULATION ER -